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to each IOL material used in each of the 4 countries.
RESULTS: Ranking the materials in the countries shows
that hydrophobic acrylic is number one in all the coun-
tries except Germany where it was second. PMMA had
the best ratio in Germany, was second in Spain and only
third in Italy and France. Silicone was second in France
and ranked third in the other countries. Hydrophilic had
the worst ratio overall in all countries. CONCLUSIONS:
Cost effectiveness ratios of hydrophobic acrylic were
better than those of the other types of IOL materials used
in most countries. Sensitivity analyses were performed to
vary the base case analysis to demonstrate the economic
importance of the assumptions. In all cases, acrylic
hydrophobic IOL material was shown to be a cost-
effective option.
PAE15
A MULTI-CENTER RETROSPECTIVE STUDY OF
RESOURCE UTILIZATION AND COSTS
ASSOCIATED WITH GLAUCOMA
MANAGEMENT IN FRANCE AND SWEDEN
Orme M1, Curry A1, Buchholz P2,Walt J3, Groleau D4,
Holmstrom S5
1Quintiles UK Ltd, Berkshire, United Kingdom; 2Allergan,
Ettlingen, Germany; 3Allergan, Irvine, CA, USA; 4Allergan UK
Ltd, Oxford, United Kingdom; 5Allergan, Mougins, France
OBJECTIVES: To assess resource utilization and direct
costs associated with managing glaucoma patients initi-
ated on medical therapy over a 2-year period in France
and Sweden. METHODS: A total of 267 adult patient
records (121 in France, 146 in Sweden) were randomly
selected from 4 sites per country based on a diagnosis of
primary open-angle glaucoma (POAG) or ocular hyper-
tension (OH). Patients had to have a minimum of 2-years
follow-up, beginning in December 1997, and started on
medical therapy at the time of study entry. Patients were
excluded based on ocular comorbidities, early glaucoma
surgical management, and prolonged hospitalization.
Records were reviewed for clinical and resource data
including intraocular pressure (IOP) measurements,
visual ﬁeld parameters, medical consultations, as well as
glaucoma medications, tests, and surgeries. Patients with
available clinical data were stratiﬁed according to sever-
ity. Resource data were assigned economic valuation to
determine direct costs from the third-party payer per-
spective. Multiple regression analyses were then per-
formed to identify the main cost drivers in treatment.
RESULTS: The total average annual direct cost of treat-
ing glaucoma was estimated at €467 patient for all
patients. In Sweden, the total annual direct cost was
higher than in France (€531 patient vs. €390 patient).
Glaucoma medication costs comprised 49% of total
direct cost in both countries. Results from the linear
regression analysis indicated that patients with the great-
est severity categories had drug costs that are 1.8–3.0
times higher, and total costs 3.6 times higher than for less
severe patients. Patients with higher baseline IOPs were
found to have higher average treatment costs. CON-
CLUSIONS: Glaucoma treatment costs in Europe are
particularly signiﬁcant for end-stage and higher baseline
IOPs patients. Treatment costs represent a substantial
proportion of direct costs. These ﬁndings suggest that
therapies targeted at efﬁcient IOP control slowing disease
progression will prove to be the most cost-efﬁcient.
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OBJECTIVE: Physicians need reliable, valid and sensitive
questionnaires to assess QoL related to glaucoma or
ocular hypertension. This abstract presents the psycho-
metric properties of the French version of the NEI-VFQ-
25. METHODS: This study was conducted with the
Sofres institute. Sending a mail survey to 20,000 house-
holds identiﬁed residents with glaucoma or ocular hyper-
tension. A random sample took part in a telephone
survey. Principal Component Analysis (PCA) and Multi-
trait analysis were performed to assess the construct
validity of the questionnaire. Internal consistency relia-
bility was assessed using Cronbach’s alpha and the
average inter-item correlation. Known-group validity was
assessed by comparing patients grouped by duration of
glaucoma, adjusted for age and gender. RESULTS: A total
of 173 patients suffering from a glaucoma or ocular
hypertension and taking treatment participated in the
survey. Twelve factors were retained by the PCA, together
explaining 84.54% of the total variance. Analysis of con-
vergent validity showed that all of the items in each scale
correlated above 0.40 with their own scale except for the
Driving scale. Success rate of the discriminant validity
ranged from 57.1% to 92.9% except for the Driving
scale, which was lower. Cronbach’s alpha coefﬁcients
were all above 0.70 excepted for the driving score. Par-
ticipants with glaucoma for less than 20 years consistently
had better Global, Near vision, Distant vision, Driving,
Social function and Peripheral vision scores than those
with 20+ years indicating better QoL. CONCLUSION:
Our results showed that the NEI-VFQ25 is a validated
instrument to measure vision-targeted QoL in French
populations with glaucoma.
